Intended for healthcare professionals

Rapid response to:

Feature

What have we learnt from Vioxx?

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39024.487720.68 (Published 18 January 2007) Cite this as: BMJ 2007;334:120

Rapid Response:

Re: On Selective Learning

What did we learn?
That a drug can be marketed to physicians in such a way that they will
prescribe
this for patients at 10 times the cost of over the counter anti-
inflammatories
when it was never demonstrated to be better or safer in terms of real
clinical
outcomes. I suppose that we can blame Merck and the FDA for promoting and

approving the use of Vioxx but they were not responsible for choosing to
prescribe Vioxx over many cheaper products. Who wrote the
prescriptions...and
why? That's what we should seek to learn: the factors that result in
irrational
prescribing.

Competing interests:
None declared

Competing interests: No competing interests

16 March 2007
Mark E. McConnell
physician
54601